Implementation of a proprietary platform for preclinical in vitro drug testing

Project Information

Living Networks is a highly investment-ready startup offering a validated, patent-pending technology for preclinical and clinical drug testing using in vitro vascularized human microtissues (3D cultures). As the only company in Poland providing such functional tests, its platform includes access to specialized biological laboratories, research equipment, a qualified team, and dedicated image analysis software. The presence of blood vessels in these microtissues is critical for evaluating drug efficacy, especially for anticancer therapies and immunotherapies targeting the tumor microenvironment, and for assessing compound toxicity on microcirculation. The company has already established advanced traction, engaging in discussions and planning joint projects with major pharmaceutical corporations, mid-sized biotech firms, cosmetic companies, and startups.

Project tasks:

  • Establishing an investment-readiness roadmap in collaboration with VC partners, including due-dilligence activities and term-sheet preparation.

  • Pursuing a pilot program with a clinical partner FamiCord Tx aimed at validation of the utility of the platform in the preclinical assessment of drug candidates with special focus  on immunotherapy toxicity.

Target group:

  • Large pharmaceutical corporations.

  • Mid-sized biotechnology companies focused on drug discovery and biological compounds.

  • Biotech companies specializing in the development immunotherapies and cell therapies.

Project goals:

  • To achieve full investment readiness for Venture Capital funding within the 4-month acceleration period.

  • To validate the company's business assumptions and commercial viability through direct collaboration and testing with early adopters in the pharmaceutical and biotech sectors.

  • The successful acquisition of corporate partners to conduct pilot testing programs.

  • Securing the company's first paying client, serving as definitive proof of market demand and commercial readiness.

Effects and outcomes:

  • Successful initiation of the national phases for the PCT patent application, including the submission of all required applications and payment of official fees in target international patent offices.

  • Long-term legal security and protection of the company's key technology on a global scale.

  • The successful acquisition of corporate partners to conduct pilot testing programs.

  • Securing the company's first paying client, serving as definitive proof of market demand and commercial readiness.

Project Value and Funding Amount

Total amount of funding

129 743,68 PLN

Total cost of the project

139 458,28 PLN

#FunduszeUE#FunduszeEuropejskie

Project partners

Living Networks Sp. z o.o.

ul. Kasprzaka 44/52, 01-224 Warsaw, Poland